CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome
Metrics: PDF 733 views | HTML 978 views | ?
Mianyang Li1,*, Li Gao2,*, Zhenling Li2,*, Junzhong Sun3, Hui Zhang2, Haoqing Duan1, Yigai Ma2, Chengbin Wang1
1Department of Clinical Laboratory, Chinese PLA General Hospital, Beijing, China
2Department of Hematology, China-Japan Friendship Hospital, Beijing, China
3Department of Hematology and Oncology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China
*These authors contributed equally to this work
Yigai Ma, email: firstname.lastname@example.org
Chengbin Wang, email: email@example.com
Keywords: CTNNA1, hypermethylation, acute myeloid leukemia, clinical impact, survival
Received: May 18, 2015 Accepted: April 12, 2016 Published: April 25, 2016
The aim of this study is to evaluate the frequency of CTNNA1 hypermethylation in acute myeloid leukemia (AML) patients in an attempt to improve molecular prognostic model. CTNNA1 promoter methylation levels in 319 newly diagnosed AML patients were detected using quantitative methylation-specific polymerase chain reaction (qMS-PCR). Furthermore, hematological characteristics, cytogenetic abnormalities, and genetic mutation status were analyzed, followed by assessment of clinical impact. Our findings demonstrated that CTNNA1 hypermethylation was observed in 25% AML patients. Hypermethylation of the CTNNA1 promoter was associated with unfavorable karyotype, and also possessed the higher frequency of coexisting with ASXL1 and RUNX1 mutations. Patients with CTNNA1 hypermethylation exhibited the shorter relapse-free survival (RFS) and overall survival (OS) in the whole AML and non-M3 AML patients. Moreover, patients with the higher methylation levels had more aggressive course than those with relative lower levels. In multivariate analyses, CTNNA1 hypermethylation was an independent factor predicting for poor RFS, but not for OS. In conclusion, CTNNA1 hypermethylation may be a reliable factor for improving prognostic molecular model for AML.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.